Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jul 11

PMID 35812375

Authors

Jie Mei

Hao Wang

Honghong Fan

Junli Ding

Junying Xu

Affiliations

Soon will be listed here.

Abstract

Background: Cancer of unknown primary (CUP) is heterogeneous and has a wide variety of clinical presentations and a poor prognosis in most patients, with a median overall survival of only 6 months. The development of molecular profiling contributes to precision therapy, and targeted drugs and immune checkpoint inhibitors (ICIs) greatly promote individualized treatment.

Case Presentation: Here, we reported a case of an unfavorable subset of CUP who had a long time of survival after the immunotherapy-prominent comprehensive treatment. A 48-year-old man presented with back pain and a cough. A diagnostic work-up showed bone marrow, multiple bones, and lymph node metastasis. Lymph node pathology implies metastatic poorly differentiated cancer. Next-generation sequencing (NGS) showed no special targets, but the tumor proportion score (TPS) of programmed death-ligand 1 (PD-L1) was 80% and the tumor mutation burden (TMB) was 16.7 per million bases. After two cycles of pembrolizumab 200 mg D1 plus nanoparticle albumin-bound (nab)-paclitaxel 200 mg D1&8 (q3w), PET-CT and bone marrow aspiration cytology showed a complete response (CR). Subsequently, pembrolizumab alone was used for three months. The left inguinal lymph nodes showed new metastasis. After two cycles of the combination treatment of pembrolizumab and (nab)-paclitaxel, a partial response (PR) was achieved. After seven months, retroperitoneal lymph nodes showed new metastasis, and the sequential treatment with radiotherapy and pembrolizumab exhibited encouraging efficacy. To date, the patient has survived nearly 40 months with the combination therapy.

Conclusions: The ICI-prominent comprehensive treatment provided clinical benefit for the reported case of CUP. Thus, CUP patients with markers of benefiting from immunotherapy should be actively treated with immunotherapy to improve their prognosis.

Citing Articles

PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First-Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study.

Huang R, Li H, Li S, Shu D, Chen R, Zheng Z MedComm (2020). 2025; 6(3):e70124.

PMID: 40060196 PMC: 11885889. DOI: 10.1002/mco2.70124.

Intratumoral Collagen Deposition Supports Angiogenesis Suggesting Anti-angiogenic Therapy in Armored and Cold Tumors.

Mei J, Yang K, Zhang X, Luo Z, Tian M, Fan H Adv Sci (Weinh). 2025; 12(10):e2409147.

PMID: 39823457 PMC: 11904994. DOI: 10.1002/advs.202409147.

Exploring the molecular landscape of cancer of unknown primary: A comparative analysis with other metastatic cancers.

Andersen L, Christensen D, Kjaer A, Knudsen M, Andersen A, Laursen M Mol Oncol. 2024; 18(10):2393-2406.

PMID: 38750007 PMC: 11459033. DOI: 10.1002/1878-0261.13664.

Exceptional response to immunotherapy monotherapy in a patient with an unfavorable subset of cancer of unknown primary.

Huang X, Ren D, Sun Q, Xu X, Ding Y Quant Imaging Med Surg. 2023; 13(12):8832-8838.

PMID: 38106245 PMC: 10722074. DOI: 10.21037/qims-23-284.

Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary.

Suzuki R, Hamada K, Ohkuma R, Homma M, Tsurui T, Iriguchi N Front Oncol. 2023; 13:1231986.

PMID: 37496666 PMC: 10365966. DOI: 10.3389/fonc.2023.1231986.

References

Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y . Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol. 2021; 33(2):216-226. DOI: 10.1016/j.annonc.2021.11.009. View

Gatalica Z, Millis S, Vranic S, Bender R, Basu G, Voss A . Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget. 2014; 5(23):12440-7. PMC: 4322997. DOI: 10.18632/oncotarget.2574. View

Ross J, Wang K, Gay L, Otto G, White E, Iwanik K . Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015; 1(1):40-49. DOI: 10.1001/jamaoncol.2014.216. View

Pentheroudakis G, Golfinopoulos V, Pavlidis N . Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007; 43(14):2026-36. DOI: 10.1016/j.ejca.2007.06.023. View

Pavlidis N, Pentheroudakis G . Cancer of unknown primary site. Lancet. 2012; 379(9824):1428-35. DOI: 10.1016/S0140-6736(11)61178-1. View

Schettini F, Giuliano M, De Placido S, Arpino G . Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev. 2016; 50:129-141. DOI: 10.1016/j.ctrv.2016.09.004. View

Economopoulou P, Pentheroudakis G . Cancer of unknown primary: time to put the pieces of the puzzle together?. Lancet Oncol. 2016; 17(10):1339-1340. DOI: 10.1016/S1470-2045(16)30377-1. View

Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Perez-Fidalgo J . Melanoma of unknown primary: New perspectives for an old story. Crit Rev Oncol Hematol. 2020; 158:103208. DOI: 10.1016/j.critrevonc.2020.103208. View

Ma X, Patel R, Wang X, Salunga R, Murage J, Desai R . Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006; 130(4):465-73. DOI: 10.5858/2006-130-465-MCOHCU. View

10.

Prowse S, Shaw R, Ganeshan D, Prowse P, Hanlon R, Lewis-Jones H . The added value of 18F-fluorodeoxyglucose positron emission tomography computed tomography in patients with neck lymph node metastases from an unknown primary malignancy. J Laryngol Otol. 2013; 127(8):780-7. DOI: 10.1017/S002221511300162X. View

11.

Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y . Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022; 15(1):24. PMC: 8917703. DOI: 10.1186/s13045-022-01242-2. View

12.

Handorf C, Kulkarni A, Grenert J, Weiss L, Rogers W, Kim O . A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol. 2013; 37(7):1067-75. PMC: 5266589. DOI: 10.1097/PAS.0b013e31828309c4. View

13.

Rassy E, Pavlidis N . Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol. 2020; 17(9):541-554. DOI: 10.1038/s41571-020-0359-1. View

14.

Moran S, Martinez-Cardus A, Boussios S, Esteller M . Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol. 2017; 14(11):682-694. DOI: 10.1038/nrclinonc.2017.97. View

15.

Hainsworth J, Greco F . Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch. 2014; 464(4):393-402. DOI: 10.1007/s00428-014-1545-2. View

16.

Delgado-Bolton R, Fernandez-Perez C, Gonzalez-Mate A, Carreras J . Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med. 2003; 44(8):1301-14. View

17.

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

18.

Rassy E, Labaki C, Chebel R, Boussios S, Smith-Gagen J, Greco F . Systematic review of the CUP trials characteristics and perspectives for next-generation studies. Cancer Treat Rev. 2022; 107:102407. DOI: 10.1016/j.ctrv.2022.102407. View

19.

Rassy E, Parent P, Lefort F, Boussios S, Baciarello G, Pavlidis N . New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. Crit Rev Oncol Hematol. 2020; 147:102882. DOI: 10.1016/j.critrevonc.2020.102882. View

20.

Varadhachary G, Raber M . Carcinoma of unknown primary site. N Engl J Med. 2014; 371(21):2040. DOI: 10.1056/NEJMc1411384. View